NCT06830408View on ClinicalTrials.gov

Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

November 12, 2024

Study Completion Date

January 13, 2025

Conditions
mCRPC
Interventions
DRUG

radionuclide therapy with 177Lu-PSMA-I&T

Standard PSMA RLT with 7-8 GBq i.v. infusion of 177Lu-PSMA-I\&T performed every 6-8 weeks for 4-6 cycles, or until progression or complete response.

Trial Locations (8)

1011

CHUV, Lausanne

3010

Inselspital, Bern

4031

University Hospital Basel, Basel

5001

Kantonspital Aarau, Aarau

6000

Luzerner Kantonsspital, Lucerne

6006

St. Anna Hirslanden Klinik, Lucerne

8091

University Hospital Zurich, Zurich

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT06830408 - Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study | Biotech Hunter | Biotech Hunter